We examined recency of infection in serum samples obtained from 69 newly identified HIV-positive cases in a sample of 1000 men who have sex with men (MSM) in Bogotá. HIV antibody avidity assays were performed using the Architect HIV Ag/AB combo. Avidity indices ranged from 0.62 to 1.22, with a cut-off score below 0.80 indicative of recent infection. Two samples were classified as recent, six fell within the gray zone (0.75 to 0.85), and the remaining 61 were considered established infections. Results provided evidence of widespread, long-term, undiagnosed HIV infection, as well as an estimate of one-year incidence at .25 in the population of MSM in Bogotá. This incidence rate is approximately 8.5 times the rate estimated for the general adult population in Colombia. The large proportion of newly diagnosed cases found among individuals with established infections indicates that many MSM in Bogotá are living with HIV for extended periods without being diagnosed and treated. Greater efforts to detect and treat undiagnosed infections are crucial to decrease HIV incidence and increase maximum effectiveness of medical intervention. Given the over-representation of MSM and transgender women in the HIV epidemic in Colombia, such efforts should specifically target this population.
ReisenCAZeaMCBianchiFT. HIV testing among MSM in Bogotá, Colombia: the role of structural and individual characteristics. AIDS Educ Prev2014; 26: 328–344.
2.
ZeaMCReisenCAdel Río-GonzálezAM. HIV prevalence and awareness of positive serostatus among men who have sex with men and transgender women in Bogotá, Colombia. Am J Public Health2015; 105: 1588–1595.
3.
MontanoSMSanchezJLLaguna-torresA. Prevalences, Genotypes, and risk factors for HIV transmission in South America. J Acquir Immune Defic Syndr2005; 40: 57–64.
4.
Vallejo F, Leal L, Alzate M, et al. Prevalence and risks factors for HIV-1 among MSM and FCSW in Bogotá, Colombia. In: XIV international AIDS conference, Barcelona, July 2002, International AIDS Society – Abstract Print – 9681, p. 11,071.
5.
UNFPA (Fondo de Población de las Naciones Unidas) & MSPS (Minitserio de Salud y Protección Social). Comportamiento Sexual Y Prevalencia de VIH En Hombres Que Tienen Raciones Sexuales Con Hombres En Siete Ciudades de Colombia (Bogotá,Medellín, Cali, Barranquilla, Cúcuta, Pereira Y Cartagena), Bogotá, Colombia, 2011.
6.
Rubio MendozaMLJacobsonJOMorales-MirandaS. High HIV burden in men who have sex with men across Colombia’s largest cities: findings from an integrated biological and behavioral surveillance study. PLoS One2015; 10: 1–15.
VesgaJFCoriAvan SighemA. Estimating HIV incidence from case-report data. AIDS2014; 28: S489–S496.
9.
BuschMPPilcherCDMastroTD. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS2010; 24: 2763–2771.
10.
DuongYTQiuMDeAK. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One2012; 7: 1–9.
11.
LaeyendeckerOBrookmeyerRCousinsMM. HIV incidence determination in the United States: a multiassay approach. J Infect Dis2013; 207: 232–239.
12.
LaeyendeckerOBrookmeyerRMullisCE. Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses2012; 28: 1177–1183.
13.
MartróESuligoiBGonzálezV. Comparison of the avidity index method and the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV Infections comparison of the avidity index. J Clin Microbiol2005; 43: 6197–6199.
14.
SuligoiBButtòSGalliC. Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol2008; 41: 288–292.
15.
SuligoiBMassiMGalliC. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr2003; 32: 424–428.
16.
SuligoiBRodellaARaimondoM. Avidity Index for Anti-HIV Antibodies: comparison between third- and fourth-generation automated immunoassays avidity index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Microbiol2011; 49: 2610–2613.
17.
Incidence Assay Critical Path Working Group. More and better information to tackle HIV epidemics: towards improved HIV incidence assays. PLoS Med2011; 8: e1001045–e1001045.
HeckathornDD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl1997; 44: 174–199.
20.
HeckathornDD. Respondent-driven sampling II: Deriving valid population estimates from chain-referral respondent-driven sampling II: Deriving valid population estimates from chain-referral samples. Soc Probl2014; 49: 11–34.
21.
SalganikMJ. Respondent-driven sampling in the real world. Epidemiology2012; 23: 148–150.
22.
TabordaNACatañoJCDelgadoJC. Higher SLPI expression, lower immune activation, and increased frequency of immune cells in a cohort of Colombian HIV-1 controllers. J Acquir Immune Defic Syndr2012; 60: 12–19.
23.
GaardboJCHartlingHJGerstoftJ. Thirty years with HIV infection - Nonprogression is still puzzling: lessons to be learned from controllers and long-term nonprogressors. AIDS Res Treat2012; 2012: 161584–161584.
24.
KumarP. Long term non-progressor (LTNP) HIV infection. Indian J Med Res2013; 138: 291–293.
25.
PoropatichKSullivanDJ. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol2011; 92(Pt 2): 247–268.
26.
SabinCALundgrenJD. The natural history of HIV infection. Curr Opin HIV AIDS2013; 8: 311–317.
27.
CowanSAGerstoftJHaffJ. Stable incidence of HIV diagnoses among Danish MSM despite increased engagement in unsafe sex. J Acquir Immune Defic Syndr2012; 61: 106–111.
28.
Das M, Chu PL, Santos G, et al. Success of test and treat in San Francisco? Reduced time to virologic suppression, decreased community viral load, and fewer new HIV infections, 2004 to 2009. In: 18th conference on retroviruses and opportunistic infections (CROI), Boston, 27 February–2 March 2011.
29.
MontanerJ. Treatment as prevention within the framework of current guidelines. J Int AIDS Soc2010; 13(Suppl 4): O12–O12.
30.
WoodEKerrTMarshallBDL. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ2009; 338: b1649–b1649.
31.
ChadbornTRBasterKDelpechVC. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die?AIDS2005; 19: 513–520.
32.
EggerMMayMChêneG. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet2002; 360: 119–129.
33.
GiordanoTPBartschGZhangY. Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial. AIDS Patient Care STDS2010; 24: 287–295.
